{"entity":{"id":"paper-heetfeld-grade-3-net-erc-2015","kind":"paper","name":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","aka":[],"tldr":"Studying 204 grade 3 neuroendocrine neoplasms showed that well-differentiated tumours with a Ki-67 in the 20 to 55 percent range respond poorly to platinum chemotherapy but survive far longer than poorly differentiated carcinomas, establishing grade 3 neuroendocrine tumour as a separate disease.","summary":"Retrospective multicentre study of 204 patients with gastroenteropancreatic neuroendocrine neoplasms with Ki-67 over 20 percent, divided into well-differentiated neuroendocrine tumours and poorly differentiated carcinomas.\n\nWell-differentiated grade 3 tumours had a median survival of 99 months against 17 months for carcinomas, lower response to platinum-etoposide, and better response to alkylating agents and other tumour-type treatments; Ki-67 of 55 percent separated the groups.","asOf":"2026-09-17","links":[{"label":"Endocr Relat Cancer 2015","url":"https://doi.org/10.1530/ERC-15-0119"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/26113608/"}],"tags":[],"related":[],"cancers":["grade-3-net"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["endocrine-related-cancer"],"dependsOn":[],"notes":[],"journal":"Endocrine-related cancer","year":2015,"doi":"10.1530/ERC-15-0119","pmid":"26113608","authors":"Heetfeld M, Chougnet CN, Olsen IH, et al.","paperType":"observational","findings":["Median overall survival 99 months for grade 3 neuroendocrine tumour vs 17 months for neuroendocrine carcinoma.","Platinum response 33 percent in tumours vs higher in carcinomas."],"whatItMeans":"Grade 3 neuroendocrine tumours are treated like aggressive grade 2 tumours (somatostatin analogues, capecitabine-temozolomide, radioligand therapy) rather than with small-cell regimens.","caveats":["Retrospective and treatment was heterogeneous."],"changedPractice":true,"participants":204},"route":"/key-papers/paper-heetfeld-grade-3-net-erc-2015/","neighbours":{"cancer":[{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/"}],"journal":[{"id":"endocrine-related-cancer","kind":"journal","name":"Endocrine-related cancer","route":"/journals/endocrine-related-cancer/"}]}}